Cardiovascular Systems

Cardiovascular Systems EBIT/Assets

Delisted

The Operating Income to Assets Ratio (EBIT/Assets) of Cardiovascular Systems (CSII) as of Nov 16, 2026 is -11.10 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -3.38 % — a change of 227.85% (lower).

EBIT/Assets

-11.10 %

YoY

227.85%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Cardiovascular Systems is 2022 -11.10 % . Operating Income to Assets Ratio (EBIT/Assets) of Cardiovascular Systems was 2021 -3.38 % . It decreases by 227.85% lower compared to the previous year.

The Cardiovascular Systems EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2015
-19.05 USD
Jan 1, 2016
-39.34 USD
Jan 1, 2017
-0.82 USD
Jan 1, 2018
1.75 USD
Jan 1, 2019
-0.38 USD
Jan 1, 2020
-7.89 USD
Jan 1, 2021
-3.38 USD
Jan 1, 2022
-11.10 USD
The Cardiovascular Systems EBIT/Assets history
YEAREBIT/AssetsYoY
-11.10 %+227.85%
-3.38 %-57.08%
-7.89 %+1,989.14%
-0.38 %-121.55%
1.75 %-313.73%
-0.82 %-97.92%
-39.34 %+106.52%
-19.05 %+3.47%
-18.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardiovascular Systems Stock analysis

What does Cardiovascular Systems do? Cardiovascular Systems Inc. (CSI) is a US medical technology company founded in 1989. The company is headquartered in St. Paul, Minnesota and employs approximately 1,000 employees worldwide. CSI develops, manufactures, and distributes innovative devices for the treatment of vascular diseases. The business model of CSI is based on the development and marketing of medical devices for minimally invasive treatment of vascular diseases. The company generates a significant portion of its revenues through the sale of its products to hospitals and specialized healthcare facilities. Additionally, CSI also offers training and educational programs for doctors and medical personnel to optimize the use of their devices. CSI operates in two main segments: peripheral arterial disease (PAD) and coronary heart disease (CHD). The PAD segment includes devices for the treatment of vascular diseases outside of the heart, such as peripheral arterial occlusive disease (PAOD). This includes the Diamondback-360® catheter and the Stealth 360® catheter, both used for plaque ablation in the arteries. The CHD segment focuses on the treatment of heart diseases such as coronary artery disease (CAD). This includes the Orbital Atherectomy System (OAS), a device that can reduce the use of stents in patients with more severe coronary artery narrowings. CSI's core product is the Diamondback-360® catheter, which was approved by the US Food and Drug Administration (FDA) in 2013. This device consists of a rotating catheter inserted into the artery to remove plaque causing vessel narrowing. The Diamondback-360 catheter is used for the treatment of PAD and has the potential to significantly improve patients' quality of life. Another important product from CSI is the Orbital Atherectomy System (OAS), used for the treatment of CAD. The OAS system is a rotating catheter that can remove plaque in the coronary arteries to improve blood flow. The use of OAS can potentially avoid costly and invasive procedures such as coronary angiography or bypass. In summary, Cardiovascular Systems Inc. is a leading company in the development and production of innovative devices for minimally invasive treatment of vascular diseases. The company specializes in two main segments, peripheral arterial disease and coronary heart disease. With products like the Diamondback-360 catheter and the Orbital Atherectomy System, CSI has established itself as a reliable provider of high-quality medical devices. Through training and educational programs, CSI also contributes to improving medical care and the development of treatment methods. Cardiovascular Systems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cardiovascular Systems stock

Operating Income to Assets Ratio (EBIT/Assets) of Cardiovascular Systems is -11.10 % in 2022.

Operating Income to Assets Ratio (EBIT/Assets) of Cardiovascular Systems changed from -3.38 % to -11.10 %, representing a 227.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Cardiovascular Systems since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Cardiovascular Systems with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Cardiovascular Systems

All Key Metrics — Cardiovascular Systems